M&A / Deals Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data BioSpaceAnother bidder, which remains unidentified, dropped out of the bidding process.M&A / DealsHematologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) BioSpace Another bidder, which remains unidentified, dropped out of the bidding process. M&A / DealsHematologyRead full story Post navigation Previous: List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)Next: Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026